Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature

Caryn Sorge, Rong Li, Sumit Singh, Alyssa T. Reddy, David A. Solomon, Arie Perry, Gregory K. Friedman

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Anaplastic oligodendroglioma (AO) is rare in children. Treatment typically consists of varying combinations of surgery, chemotherapy, and radiotherapy. We present a pediatric case of frontal lobe AO with periventricular subcallosal extension and local leptomeningeal involvement. The isocitrate dehydrogenase (IDH) wild-type tumor was MGMT methylated and contained an ATRX mutation, BRAF alteration, and 1p/19q co-deletion; a combination of alterations mostly encountered in pediatric oligodendrogliomas. The patient underwent a near total resection and had a complete, durable response to temozolomide alone, suggesting that conservative management without radiation may be appropriate in some cases. We review the literature of this uncommon subtype of glioma in children.

Original languageEnglish (US)
Article numbere26708
JournalPediatric Blood and Cancer
Volume64
Issue number12
DOIs
StatePublished - Dec 2017
Externally publishedYes

Keywords

  • 1p19q
  • children
  • codeletion
  • oligodendroglioma
  • pediatric
  • temozolomide

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Complete durable response of a pediatric anaplastic oligodendroglioma to temozolomide alone: Case report and review of literature'. Together they form a unique fingerprint.

Cite this